HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BI 836826

Fc-engineered CD37 antibody with cytotoxic activity against chronic lymphocytic leukemia (CLL) cells

Also Known As:

BI-836826

Networked: 6 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Quinson, Anne-Marie: 5 articles (02/2021 - 10/2020)
2.	von Wangenheim, Ute: 4 articles (02/2021 - 10/2019)
3.	Berk, Andreas: 3 articles (02/2021 - 10/2020)
4.	Bouabdallah, Reda: 3 articles (02/2021 - 10/2020)
5.	Burkard, Ute: 3 articles (02/2021 - 10/2020)
6.	Chromik, Joerg: 3 articles (02/2021 - 10/2020)
7.	Janz, Martin: 3 articles (02/2021 - 10/2020)
8.	Kim, Seok Jin: 3 articles (02/2021 - 10/2020)
9.	Kim, Tae Min: 3 articles (02/2021 - 10/2020)
10.	Kroschinsky, Frank: 3 articles (02/2021 - 10/2020)

Related Diseases

1.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/01/2021 - "This open-label, phase I dose-escalation trial (NCT02624492) was conducted to determine the maximum tolerated dose (MTD), safety/tolerability, and preliminary efficacy of BI 836826 in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). " 01/01/2021 - "A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma."
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/01/2021 - "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma." 02/01/2021 - "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma." 10/01/2020 - "This phase I, open-label study used a modified 3 + 3 design to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics, and preliminary activity of BI 836826 in patients with relapsed/refractory B cell non-Hodgkin lymphoma (NHL; NCT01403948). " 10/01/2020 - "Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma."
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/01/2019 - "Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia." 01/01/2021 - "A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia."
4.	Thrombocytopenia (Thrombopenia) 01/01/2021 - "The most common adverse events related to BI 836826 treatment were neutropenia (52%), thrombocytopenia (48%), and anemia (48%). "
5.	Neutropenia 01/01/2021 - "The most common adverse events related to BI 836826 treatment were neutropenia (52%), thrombocytopenia (48%), and anemia (48%). "

Related Drugs and Biologics

1.	Gemcitabine
2.	Oxaliplatin (Eloxatin)
3.	Monoclonal Antibodies
4.	ibrutinib